RxDoctor Payments Data

Alexander Baten-Tschan

Glaucoma Specialist · Bethesda, MDNPI 1205333457

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Alcon accounts for 71.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $1,364 and has fallen 64.7% since, to $481 in 2025.

$2,047in general payments, 2019–2025

Across 30 payments — averaging $68.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$187
  • Tarsus Pharmaceuticals, Inc.$62
  • Bausch & Lomb Americas Inc.$57
  • Dompe US, Inc.$55
  • Harrow Eye, LLC$46
  • plus $173 from 6 others

What the payments were for

  • Travel & lodging$1,06052%
  • Food & beverage$96947%
  • Education$181%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$238,603
Medicare patients
692
Services billed
2,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost76$44,278
RhopressaNetarsudil Mesylate64$33,555
CombiganBrimonidine Tartrate/Timolol31$14,261
SimbrinzaBrinzolamide/Brimonidine Tart41$14,057
Brimonidine Tartrate202$12,534
Prednisolone Acetate166$11,914
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol48$9,558
Alphagan PBrimonidine Tartrate15$6,796
VyzultaLatanoprostene Bunod13$6,647
Travoprost37$6,470
Latanoprost387$6,360
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat289$5,421
Timolol Maleate237$4,386
Brinzolamide15$3,121
Dorzolamide-TimololDorzolamide/Timolol/Pf17$3,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$187$65,335122 claims
AlconSimbrinza$1,468$14,05741 claims
Bausch & Lomb Americas Inc.Vyzulta$57$6,64713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →